Beigene, the company that created Zanubrutinib (Brukinsa), is sponsoring a session through the organization Catalytic Health. To quote from their invitation:
Who Should Attend?
This non-promotional session aims to facilitate the dialogue around Waldenström’s Macroglobulinemia between Canadian healthcare professionals, policy experts, patients and representatives from patient advocacy groups. As such, the session is geared towards medical oncologists/hematologists, nurses, pharmacists who treat patients with Waldenström’s Macroglobulinemia, members of the patient community and policy makers whose work may touch on cancer initiatives.
The Summit details:
Join us for a live, virtual and interactive program to hear from Canadian clinical and policy experts as well as Canadian patient advocacy groups about the current state of Waldenström’s Macroglobulinemia treatment, access to care and to learn about new emerging treatment therapies.
This virtual, interactive learning program will feature short presentations and panel discussions with:
Peter Anglin, MD
Nicole Laferriere, MD
Julie Stakiw, MD
Paul Kitchen, Waldenström’s Macroglobulinemia Foundation of Canada
Kaitlyn Beyfuss-Laski, Manager of Patient Programs, Research and Advocacy, Lymphoma Canada
Louise Binder, Health Policy Consultant, Save Your Skin Foundation
Martine Elias, Executive Director, Myeloma Canada
Enhance knowledge and understanding of Waldenström’s Macroglobulinemia by:
- Hearing from Canadian clinicians about the diagnosis, treatment and differing patterns of care for Waldenström’s Macroglobulinemia
- Discussing the journey and impact of Waldenström’s Macroglobulinemia for Canadian patients
- Engaging with the policy community to understand key policy challenges and gaps that need to be addressed to optimize care and access to new treatments